Acta Neurochirurgica

, Volume 152, Issue 12, pp 2063–2068 | Cite as

Cardiac 123I-MIBG scintigraphy as an outcome-predicting tool for subthalamic nucleus stimulation in Parkinson's disease

  • Kazumichi Yamada
  • Shin-ya Shiraishi
  • Tadashi Hamasaki
  • Jun-ichi Kuratsu
Clinical Article



123I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy is a useful tool for differentiating idiopathic Parkinson's disease (PD) from other parkinsonian syndromes, but its prognostic value in PD has not been established. The objective of this study was to clarify the correlation between cardiac MIBG uptake parameters and the outcome in PD patients subjected to the subthalamic nucleus stimulation.


We enrolled 31 consecutive PD patients and calculated the heart-to-mediastinum ratio (H/M) and washout rate (WR) based on the activity measured at 15 min (early phase) and 3 h (delayed phase) after the intravenous injection of MIBG (111 MBq). Cardinal motor symptoms and activity of daily living (ADL) were assessed on the Unified Parkinson's Disease Rating Scale (UPDRS) and Schwab and England (S–E) ADL scale, before and 3 months after surgery.


Neither early nor delayed H/M correlated with any of the preoperative subscores on the UPDRS or S–E, nor with postoperative outcome. On the other hand, increased WR was a positive predictor for postoperative improvement rate on S–E in medication-off state (p = 0.00003). Also, WR showed a more faint but significant correlation with preoperative levodopa responsiveness on S–E (p = 0.008).


Our findings suggest that 123I-MIBG scintigraphy in combination with levodopa-responsiveness evaluation may represent a useful tool for prediction of outcomes in patients subjected to STN stimulation.


Deep-brain stimulation 123I-MIBG Parkinson's disease Subthalamic nucleus 


  1. 1.
    Ando Y, Obayashi K, Tanaka Y, Tsuji T, Uchino M, Takahashi M, Ando M (1994) Radiolabelled metaiodobenzylguanidine in assessment of autonomic dysfunction. Lancet 343:984–985CrossRefPubMedGoogle Scholar
  2. 2.
    Braak H, Tredici KD, Rüb U, de Vos RAI, Ernst NH, Steur ENHJ, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197–211CrossRefPubMedGoogle Scholar
  3. 3.
    Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson G, Benabid AL, Pollak P (2002) Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 59:932–934PubMedGoogle Scholar
  4. 4.
    Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH (2009) MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism- predominant multiple system atrophy. Mov Disord 24:1650–1655CrossRefPubMedGoogle Scholar
  5. 5.
    Erola T, Heikkinen ER, Haapaniemi T, Tuominen J, Juolasmaa A, Myllylä VV (2006) Efficacy of bilateral subthalamic nucleus (STN) stimulation in Parkinson's disease. Acta Neurochir (Wien) 148:389–394CrossRefGoogle Scholar
  6. 6.
    Hakusui S, Yasuda T, Yanagi T, Tohyama J, Hasegawa Y, Koike Y, Hirayama M, Takahashi A (1994) A radiological analysis of heart sympathetic functions with meta-[123I] iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 49:81–84CrossRefPubMedGoogle Scholar
  7. 7.
    Hallett M, Litvan I (1999) The task force on surgery for Parkinson's disease. Evaluation of surgery for Parkinson's disease. A report of the therapeutic and technology assessment subcommittee of the American academy of neurology. Neurology 53:1910–1921PubMedGoogle Scholar
  8. 8.
    Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, Satoh A, Seto M, Tsujihata M, Takahashi H (1999) Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body disease. Neurology 52:1269–1271PubMedGoogle Scholar
  9. 9.
    Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, Sato Y, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M (2008) Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 49:907–914CrossRefPubMedGoogle Scholar
  10. 10.
    Katayama Y, Kasai M, Oshima H, Fukaya C, Yamamato T, Ogawa K, Mizutani T (2001) Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients. J Neurosurg 95:213–221CrossRefPubMedGoogle Scholar
  11. 11.
    Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G (2006) Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21(Suppl 14):S290–S304CrossRefPubMedGoogle Scholar
  12. 12.
    Krack P, Batir A, van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin P, Benazzouz A, LeBas JF, Benabid A-L, Pollak P (2003) A five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Eng J Med 349:1925–1934CrossRefGoogle Scholar
  13. 13.
    Langston JW (2006) The Parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 59:591–596CrossRefPubMedGoogle Scholar
  14. 14.
    Lyons KE, Davis JT, Pahwa R (2007) Subthalamic stimulation in Parkinson's disease patients intolerant to levodopa. Stereotact Funct Neurosurg 85:169–174CrossRefPubMedGoogle Scholar
  15. 15.
    Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P (1992) Bourguignon MH, Benvenuti C, Duval AM, Agostini D, Loisance D, Castaigne A, Syrota A. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33:471–477PubMedGoogle Scholar
  16. 16.
    Moro E, Scerrati M, Romito LMA, Roselli R, Tonali P, Albanese A (1999) Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53:85–90PubMedGoogle Scholar
  17. 17.
    Nagamachi S, Wakamatsu H, Kiyohara S, Fujita S, Futami S, Tamura S, Nakazato M, Yamashita S, Arita H, Nishii R, Kawai K (2008) Usefulness of rCBF analysis in diagnosing Parkinson's disease: supplemental role with MIBG myocardial scintigraphy. Ann Nucl Med 22:557–564CrossRefPubMedGoogle Scholar
  18. 18.
    Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 76:249–251CrossRefPubMedGoogle Scholar
  19. 19.
    Orimo S, Ozawa E, Oka T, Nakade S, Tsuchiya K, Yoshimoto M, Wakabayashi K, Takahashi H (2001) Differentional histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 57:1140–1141PubMedGoogle Scholar
  20. 20.
    Østergaard K, Sunde N, Dupont E (2002) Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 17:693–700CrossRefPubMedGoogle Scholar
  21. 21.
    Post KK, Singer C, Papapetropoulos S (2008) Cardiac denervation and dysautonomia in Parkinson's disease: a review of screening techniques. Parkinsonism Relat Disord 14:524–531CrossRefPubMedGoogle Scholar
  22. 22.
    Romito LM, Scerrati M, Contarino MF, Bentivoglio AR, Tonali P, Albanese A (2002) Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease. Neurology 58:1546–1550PubMedGoogle Scholar
  23. 23.
    Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K (2000) Tonami N (2000) Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27:566–573CrossRefPubMedGoogle Scholar
  24. 24.
    Taki J, Yoshita M, Yamada M, Tonami N (2004) Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med 18:453–461CrossRefPubMedGoogle Scholar
  25. 25.
    Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL (2008) Prognostic value of myocardinal 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systemic review. Eur Heart J 29:1147–1159CrossRefPubMedGoogle Scholar
  26. 26.
    Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J (2002) Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 58:396–401PubMedGoogle Scholar
  27. 27.
    Welter ML, Houeto JL, Tezenas du Montcel S, Mesnage V, Bonnet AM, Pillon B, Agid Y et al (2002) Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 125:575–583CrossRefPubMedGoogle Scholar
  28. 28.
    Yamada K, Goto S, Hamasaki T, Kuratsu J-I (2008) Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease. Acta Neurochir (Wien) 150:15–22CrossRefGoogle Scholar
  29. 29.
    Yamada K, Goto S, Kuratsu J, Matsuzaki K, Nagahiro S, Shimazu H, Kaji R (2007) General anesthesia for stereotactic implantation of stimulating electrodes within the subthalamic nucleus. Parkinsonism Relat Disord 13:101–107CrossRefPubMedGoogle Scholar
  30. 30.
    Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K, Yamada M (2006) 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66:1850–1854CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Kazumichi Yamada
    • 1
  • Shin-ya Shiraishi
    • 2
  • Tadashi Hamasaki
    • 3
  • Jun-ichi Kuratsu
    • 1
  1. 1.Department of Neurosurgery, Graduate School of Life SciencesKumamoto UniversityKumamotoJapan
  2. 2.Department of Diagnostic Imaging, Graduate School of Life SciencesKumamoto UniversityKumamotoJapan
  3. 3.Department of NeurosurgeryNational Hospital Organization Kagoshima Medical CenterKagoshimaJapan

Personalised recommendations